Skip to content
OpenCapital
Get started

Allogene Therapeutics ALLO Cash Equivalents And Short Term Investments

Other financials

Income statement

See full
Revenue-—
Operating income-$46.1M+29.3%
Net income-$42.6M+28.7%
EPS (diluted)-$0.18+35.7%

Balance sheet

See full
Cash & equivalents$40.6M-23.0%
Total debt$81.1M-8.9%
Total equity$278.9M-27.6%
Total assets$396.0M-22.1%

Cash flow

See full
Operating cash flow-$12.9M+75.6%
CapEx$9.0K-90.9%
Free cash flow-$12.9M+75.6%

Valuation

See full
Market cap$711.02M+164%
Enterprise value$751.47M+146%

Profitability

See full
Operating margin-1,241,813.6%-2,018,140pp
Net margin-1,170,863.6%-2,007,890pp
FCF margin-913,609.1%-1,474,890pp

Returns & leverage

See full
Return on equity-52.3%-5.7pp
Debt / equity0.3×+0.1×
Current ratio9.6×-0.1×

Where this comes from

Reported directly by Allogene Therapeutics in its filing.

Tagged under the XBRL concept allo:CashEquivalentsAndShortTermInvestments.

The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Allogene Therapeutics's cash equivalents and short term investments.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Allogene Therapeutics's cash equivalents and short term investments?
Allogene Therapeutics (ALLO) reported cash equivalents and short term investments of $261.63M in Q1 2026.
How has Allogene Therapeutics's cash equivalents and short term investments changed year-over-year?
Allogene Therapeutics's cash equivalents and short term investments decreased by 21.0% year-over-year, from $331.23M to $261.63M.
What is the long-term trend for Allogene Therapeutics's cash equivalents and short term investments?
Over 5 years (2020 to 2025), Allogene Therapeutics's cash equivalents and short term investments has grown at a -23.1% compound annual growth rate (CAGR), from $950.81M to $255.14M.